Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VKTX | Viking Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-0.91 Insider Own5.89% Shs Outstand99.01M Perf Week-11.27%
Market Cap1.35B Forward P/E- EPS next Y-1.02 Insider Trans-16.33% Shs Float93.71M Perf Month-7.38%
Income-74.10M PEG- EPS next Q-0.22 Inst Own35.70% Short Float / Ratio13.78% / 5.74 Perf Quarter-38.94%
Sales- P/S- EPS this Y-25.80% Inst Trans-0.31% Short Interest12.91M Perf Half Y38.94%
Book/sh3.90 P/B3.41 EPS next Y-13.30% ROA-33.40% Target Price33.80 Perf Year333.55%
Cash/sh3.87 P/C3.44 EPS next 5Y40.00% ROE-36.30% 52W Range2.53 - 25.72 Perf YTD41.60%
Dividend- P/FCF- EPS past 5Y-2.50% ROI- 52W High-48.25% Beta0.53
Dividend %- Quick Ratio29.60 Sales past 5Y- Gross Margin- 52W Low425.15% ATR0.74
Employees22 Current Ratio29.60 Sales Q/Q- Oper. Margin- RSI (14)37.39 Volatility5.42% 4.89%
OptionableYes Debt/Eq0.00 EPS Q/Q14.40% Profit Margin- Rel Volume0.49 Prev Close13.49
ShortableYes LT Debt/Eq0.00 EarningsJul 26 AMC Payout- Avg Volume2.25M Price13.31
Recom1.50 SMA20-7.47% SMA50-8.03% SMA200-7.37% Volume1,099,159 Change-1.33%
Date Action Analyst Rating Change Price Target Change
May-31-23Resumed ROTH MKM Buy $32
Mar-28-23Reiterated Maxim Group Buy $15 → $25
Mar-17-23Initiated Stifel Buy $22
Jul-29-21Resumed BTIG Research Buy $20
May-25-21Downgrade Raymond James Strong Buy → Outperform $27 → $12
Jun-05-20Initiated BMO Capital Markets Outperform $14
May-05-20Initiated Chardan Capital Markets Buy $15
May-01-20Initiated BTIG Research Buy $9
Jul-16-19Initiated Oppenheimer Outperform $12
Jun-25-19Initiated Stifel Buy
Sep-07-23 04:05PM
Sep-06-23 07:03AM
Aug-28-23 10:22AM
Aug-17-23 09:31AM
Aug-16-23 07:07PM
11:45AM Loading…
Aug-09-23 11:45AM
Aug-08-23 11:45AM
Aug-02-23 11:15AM
Jul-29-23 11:39AM
Jul-27-23 09:51AM
Jul-26-23 04:05PM
Jul-22-23 06:14AM
Jul-19-23 04:05PM
Jul-12-23 10:05AM
Jul-10-23 09:32AM
09:29AM Loading…
09:29AM
Jul-07-23 06:32PM
08:00AM
Jul-05-23 08:14PM
Jun-29-23 02:00PM
08:30AM
Jun-27-23 01:53PM
Jun-26-23 11:39PM
Jun-22-23 06:40AM
Jun-20-23 10:15AM
05:50AM
05:25AM
Jun-17-23 09:06AM
Jun-13-23 11:15AM
Jun-12-23 10:15AM
11:14AM Loading…
Jun-08-23 11:14AM
10:07AM
Jun-07-23 07:13AM
May-31-23 02:49PM
May-30-23 05:38AM
May-26-23 06:19AM
May-24-23 11:59AM
May-22-23 12:02PM
06:40AM
May-21-23 03:28PM
May-19-23 03:27PM
May-18-23 02:52PM
12:12PM
May-17-23 01:59PM
May-16-23 04:12PM
03:52PM
11:29AM
09:32AM
07:31AM
07:00AM
May-11-23 08:39AM
May-09-23 03:40PM
May-01-23 04:28PM
Apr-27-23 02:56PM
06:31AM
Apr-26-23 04:05PM
Apr-25-23 08:45AM
07:12AM
Apr-20-23 04:05PM
Apr-19-23 02:42PM
Apr-11-23 04:05PM
Apr-07-23 06:40PM
Apr-03-23 05:06PM
Apr-01-23 01:43PM
Mar-30-23 02:06PM
01:48AM
Mar-29-23 04:10PM
04:01PM
12:51PM
11:24AM
07:45AM
05:54AM
Mar-28-23 04:18PM
04:18PM
12:32PM
07:03AM
07:00AM
06:33AM
Mar-27-23 05:47AM
Mar-15-23 03:28PM
Mar-07-23 04:05PM
Feb-23-23 10:30AM
Feb-11-23 07:05AM
Feb-08-23 04:05PM
Feb-07-23 04:05PM
Feb-01-23 04:05PM
Jan-12-23 06:06AM
Jan-09-23 07:05AM
Dec-28-22 09:29PM
Dec-19-22 08:42AM
Dec-09-22 12:00PM
Nov-22-22 08:30AM
Nov-16-22 06:01AM
Nov-08-22 04:05PM
Oct-26-22 04:05PM
Oct-19-22 04:05PM
Oct-06-22 03:09PM
Sep-15-22 11:38AM
Sep-06-22 04:05PM
Aug-05-22 06:51AM
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rowland Charles A JrDirectorMay 16Option Exercise1.0840,00043,20070,000May 18 06:31 PM
MACARTNEY LAWSONDirectorMay 16Option Exercise1.1916,00019,04063,965May 18 06:30 PM
Rowland Charles A JrDirectorMay 16Sale25.0040,0001,000,00030,000May 18 06:31 PM
MACARTNEY LAWSONDirectorMay 16Sale24.0016,000384,00047,965May 18 06:30 PM
Lian BrianPresident & CEOMay 01Sale22.4545,0001,010,2502,197,963May 01 07:03 PM
MACARTNEY LAWSONDirectorApr 24Option Exercise3.3316,00053,28063,965Apr 24 07:31 PM
MACARTNEY LAWSONDirectorApr 24Sale22.0016,000352,06147,965Apr 24 07:31 PM
Lian BrianPresident & CEOApr 19Sale21.4535,000750,7502,242,963Apr 21 07:29 PM
Lian BrianPresident & CEOApr 17Option Exercise2.15125,000268,7502,432,963Apr 18 07:09 PM
MACARTNEY LAWSONDirectorApr 17Option Exercise8.0020,786166,28868,751Apr 18 07:10 PM
Mancini MariannaChief Operating OfficerApr 17Option Exercise13.0712,500163,375300,263Apr 18 07:08 PM
ZANTE GREGChief Financial OfficerApr 17Option Exercise13.077,50098,025156,779Apr 18 07:07 PM
Lian BrianPresident & CEOApr 17Sale20.45155,0003,169,7662,277,963Apr 18 07:09 PM
MACARTNEY LAWSONDirectorApr 17Sale20.0020,786415,72047,965Apr 18 07:10 PM
Mancini MariannaChief Operating OfficerApr 17Sale20.0012,500250,000287,763Apr 18 07:08 PM
ZANTE GREGChief Financial OfficerApr 17Sale20.007,500150,000149,279Apr 18 07:07 PM
Lian BrianPresident & CEOApr 13Option Exercise1.8854,336102,1522,387,299Apr 13 05:14 PM
Lian BrianPresident & CEOApr 13Sale18.4579,3361,463,7492,307,963Apr 13 05:14 PM
ZANTE GREGChief Financial OfficerApr 12Option Exercise5.9941,544249,026190,823Apr 13 05:13 PM
ZANTE GREGChief Financial OfficerApr 12Sale18.0041,544747,792149,279Apr 13 05:13 PM
ZANTE GREGChief Financial OfficerApr 11Option Exercise5.2556,295295,778205,574Apr 13 05:13 PM
ZANTE GREGChief Financial OfficerApr 11Sale18.0056,2951,013,518149,279Apr 13 05:13 PM
ZANTE GREGChief Financial OfficerApr 03Option Exercise7.7730,911240,178178,689Apr 03 07:24 PM
ZANTE GREGChief Financial OfficerApr 03Sale18.0030,911556,398147,778Apr 03 07:24 PM
Lian BrianPresident & CEOApr 03Sale17.8522,000392,7002,232,963Apr 03 07:26 PM
Lian BrianPresident & CEOMar 31Option Exercise9.4967,970645,0352,322,933Apr 03 07:26 PM
Lian BrianPresident & CEOMar 31Sale17.4567,9701,186,0762,254,963Apr 03 07:26 PM
ZANTE GREGChief Financial OfficerMar 30Option Exercise7.2993,750683,482278,807Apr 03 07:24 PM
Lian BrianPresident & CEOMar 30Option Exercise2.42135,382327,8382,408,345Apr 03 07:26 PM
Mancini MariannaChief Operating OfficerMar 30Option Exercise8.1236,100293,122297,995Apr 03 07:22 PM
Lian BrianPresident & CEOMar 30Sale17.16153,3822,632,5162,254,963Apr 03 07:26 PM
ZANTE GREGChief Financial OfficerMar 30Sale17.00131,0292,227,821147,778Apr 03 07:24 PM
Mancini MariannaChief Operating OfficerMar 29Option Exercise9.1315,000136,950303,137Mar 30 09:04 PM
Mancini MariannaChief Operating OfficerMar 29Sale16.0041,242659,872261,895Mar 30 09:04 PM
Mancini MariannaChief Operating OfficerMar 28Option Exercise2.37167,427397,193484,700Mar 30 09:04 PM
Mancini MariannaChief Operating OfficerMar 28Sale15.00196,5632,948,445288,137Mar 30 09:04 PM